Poland· PL-100212265
Berinert 500
A c1-inhibitor, plasma derived product containing inhibitor c1-esterazy, ludzki, registered in Poland by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
C1-inhibitor, plasma derived is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
C1-inhibitor, plasma derived · ATC B06AC01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Inhibitor C1-esterazy, ludzki
- Manufacturer
- CSL Behring GmbH
- Country
- Poland (PL)
- ATC code
- B06AC01
- ATC class
- C1-inhibitor, plasma derived
- Defined daily dose
- 1.4 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- gtin059099907136391 fiol. z prosz. + 1 fiol. z rozp. + 1 zestaw do podawaniaPLN 2397.22
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
47 interactions on record for c1-inhibitor, plasma derived.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
C1-inhibitor, plasma derived · interactions on record
47 records
- 5 severe
- 42 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B06AC01
C1-inhibitor, plasma derived, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d85ae80f-c892-4b19-94c9-8d5acaf72696 GET /v1/drugs/d85ae80f-c892-4b19-94c9-8d5acaf72696?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań lub do infuzji",
"source": "urpl",
"strength": "500 j.m./ml",
"packaging": "05909990713639 ¦ Rp ¦ 51605\n1 fiol. proszku ¦ 1 system do transferu 20/20 z filtrem ¦ 1 fiol. 10 ml rozp.",
"substance": "Inhibitor C1-esterazy, ludzki 40,0 - 62,5 J/ml",
"common_name": "Inhibitor C1-esterazy, ludzki",
"pl_product_id": "100212265",
"pozwolenie_nr": "15705",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about c1-inhibitor, plasma derived.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.